BWAY - חוב להון עצמי BrainsWay Ltd

BrainsWay Ltd. (BWAY) leads the neurostimulation sector, utilizing patented H-coils for the non-drug treatment of OCD and depression. The brand's high authority among psychiatrists is based on the safety and efficacy of the Deep TMS method. This price action reflects a dependence on equipment procurement by clinics, while the total debt-to-equity ratio stands at 0.09, confirming liquidity stability.

Diversifying magnetic brain stimulation systems across various pathologies requires stable funding for expansion. By analyzing the debt-to-equity ratio, an investor assesses the stability of the liability structure of BrainsWay Ltd. (BWAY). This metric compares total liabilities to net assets, determining the business's degree of dependence on borrowed funds. A low value confirms financial autonomy during global scaling, while a high ratio signals risks of capital degradation.